Lantern Pharma (LTRN) Tops Q4 EPS by 1c

Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UBS Reiterates Buy Rating on PVH Corp (PVH) on Strong Earnings Growth Potential
• BlackRock’s Rosenberg says inflation data key after jobs beat